Skip to main content
. 2023 Oct 14;36(9):2531–2540. doi: 10.1007/s40620-023-01760-3

Table 1.

Baseline characteristics

Overall (n = 1042) No AKI (n = 761) AKI (n = 267) p
Sex (male, n, %) 710 (68.1) 507 (66.6) 193 (72.3) 0.088
Age (median, IQR) 66.0 (56.0–75.0) 65.0 (54.0–74.0) 70.0 (59.0–78.0)  < 0.001
Age group (n, %)
  < 40 62 (6.0) 56 (7.4) 6 (2.2)  < 0.001
 40–60 297 (28.5) 231 (30.4) 65 (24.3)
 60–80 558 (53.6) 398 (52.3) 152 (56.9)
  > 80 125 (12.0) 76 (10.0) 44 (16.5)
SOFA Score (median, IQR) 5.0 (4.0–7.0) 4.0 (3.0–6.0) 7.0 (4.0–9.0)  < 0.001
SAPS 3 (median, IQR) 53.0 (46.0–61.0) 51.0 (46.0–60.0) 58.0 (51.0–65.0)  < 0.001
Comorbidities
 Hypertension (n, %) 600 (57.6) 406 (53.4) 186 (69.7)  < 0.001
 Cardiovascular (n, %) 387 (37.1) 252 (33.1) 131 (49.1)  < 0.001
 Obesity (BMI > 30) (n, %) 322 (32.1) 239 (32.7) 82 (31.4) 0.695
 Diabetes mellitus (n, %)
  No Diabetes 729 (70.4) 532 (70.4) 185 (69.8) 0.830
  DM Type 1 10 (1.0) 8 (1.1) 2 (0.8)
  DM Type 2 241 (23.3) 174 (23.0) 66 (24.9)
  Prediabetes 55 (5.3) 42 (5.6) 12 (4.5)
 Chronic kidney disease (n, %) 197 (18.9) 110 (14.5) 83 (31.1)  < 0.001
 Hepatic (n, %) 88 (8.4) 56 (7.4) 31 (11.6) 0.032
 Hematological malignancy (n, %) 53 (5.1) 33 (4.3) 18 (6.7) 0.119
 Non hematological malignancy (n, %) 73 (7.0) 51 (6.7) 20 (7.5) 0.666
 Immunosuppression (n, %) 73 (7.0) 47 (6.2) 25 (9.4) 0.079
 COPD (n, %) 129 (12.4) 89 (11.7) 40 (15.0) 0.163
 Asthma (n, %) 45 (4.3) 34 (4.5) 11 (4.1) 0.811
 Other respiratory (n, %) 77 (7.4) 50 (6.6) 27 (10.1) 0.059
 No known comorbidity (n, %) 138 (13.8) 122 (16.8) 14 (5.4)  < 0.001
Symptom onset to hospitalization (median, IQR) 6 (4–9) 6 (4–9) 6 (3–9) 0.704
Symptom onset to ICU admission (median, IQR) 8 (5–11) 9 (6–11) 8 (5–11) 0.055

SOFA sequential organ failure assessment, SAPS 3 simplified acute physiology score 3, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, ICU intensive care unit